Enanta Pharmaceuticals (ENTA) News Today $8.03 -0.35 (-4.18%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$8.05 +0.02 (+0.26%) As of 02/21/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to "Hold" at StockNews.comStockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.February 19 at 2:18 AM | marketbeat.comEnanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlookFebruary 17, 2025 | msn.comAnalysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25February 17, 2025 | americanbankingnews.comWith Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their ReturnsFebruary 15, 2025 | finance.yahoo.comPresident of Enanta Pharmaceuticals Picks Up 5.9% More StockFebruary 15, 2025 | finance.yahoo.comHC Wainwright Issues Negative Estimate for ENTA EarningsFebruary 15, 2025 | americanbankingnews.comJMP Securities Reaffirms Market Outperform Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)February 14, 2025 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendaFebruary 14, 2025 | marketbeat.comEnanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stockFebruary 13, 2025 | msn.comEnanta Pharmaceuticals (ENTA) Receives a Buy from Evercore ISIFebruary 13, 2025 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for ENTA EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Arce now antiFebruary 13, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Buys $256,050.00 in StockFebruary 13, 2025 | insidertrades.comJay R. Luly Purchases 45,000 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) CEO Jay R. Luly bought 45,000 shares of the firm's stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the transaction, the chief executive officer now owns 846,638 shares of the company's stock, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to Sell at StockNews.comStockNews.com downgraded Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday.February 11, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)JMP Securities restated a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comEnanta reports Q1 EPS ($1.05), consensus ($1.35)February 11, 2025 | markets.businessinsider.comJMP Securities maintains Enanta stock with $21 targetFebruary 11, 2025 | msn.comHC Wainwright maintains $18 target on Enanta shares, affirms BuyFebruary 11, 2025 | msn.comHC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPSEnanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.February 10, 2025 | marketbeat.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024February 10, 2025 | businesswire.comEnanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on WednesdayEnanta Pharmaceuticals (NASDAQ:ENTA) will be releasing earnings before the market opens on Wednesday, February 5, Financial Modeling Prep reports.January 29, 2025 | marketbeat.comAssenagon Asset Management S.A. Raises Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. lifted its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 34.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,856 shares of the biotechnology company's stock aftJanuary 25, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)JPMorgan Chase & Co. grew its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 53.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,628 shares of the biotechnolJanuary 21, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendatJanuary 20, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) Receives a Hold from Leerink PartnersJanuary 18, 2025 | markets.businessinsider.comEnanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | uk.finance.yahoo.comQ1 Earnings Estimate for ENTA Issued By HC WainwrightEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Enanta Pharmaceuticals in a note issued to investors on Tuesday, December 24th. HC Wainwright analyst E. Arce anticipates that the biotechnology company wilDecember 27, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and onDecember 26, 2024 | marketbeat.comEnanta to appeal ruling related to ‘953 patent infringement lawsuitDecember 25, 2024 | markets.businessinsider.comEquities Analysts Set Expectations for ENTA FY2029 EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a research report issued on Tuesday, December 24th. HC Wainwright analyst E. Arce expects that the biotechnology coDecember 25, 2024 | marketbeat.comEnanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement LawsuitDecember 25, 2024 | uk.finance.yahoo.comEnanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)December 25, 2024 | benzinga.comEnanta Plans To Appeal Court Ruling Related To 953 Patent Infringement LawsuitDecember 25, 2024 | markets.businessinsider.comPromising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment ConcernsDecember 25, 2024 | markets.businessinsider.comHC Wainwright Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock PriceHC Wainwright dropped their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday.December 24, 2024 | marketbeat.comEnanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy BuchananDecember 14, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)December 12, 2024 | markets.businessinsider.comEquities Analysts Set Expectations for ENTA FY2025 EarningsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Enanta Pharmaceuticals in a research note issued on Monday, December 9th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology companDecember 12, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA) Gets a Hold from OppenheimerDecember 11, 2024 | markets.businessinsider.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Tara Lynn Kieffer Sells 2,283 SharesDecember 11, 2024 | insidertrades.comPoint72 Asset Management L.P. Acquires Shares of 87,190 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Point72 Asset Management L.P. bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 87,190 shares of the biotechnology company's stock,December 11, 2024 | marketbeat.comEnanta Reports Positive Phase 2 Data For Zelicapavir In Paediatric RSV Study; Stock UpDecember 9, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)December 9, 2024 | businesswire.comEnanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)December 6, 2024 | businesswire.comErste Asset Management GmbH Buys Shares of 120,000 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Erste Asset Management GmbH purchased a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 120,000 shares of the bioteDecember 4, 2024 | marketbeat.comCaligan Partners LP Cuts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Caligan Partners LP decreased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 69.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 322,453 shares of the bioteDecember 1, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recoDecember 1, 2024 | marketbeat.comEnanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlookNovember 30, 2024 | investing.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024November 27, 2024 | businesswire.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼-0.080.60▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼72▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMTX News Today ORIC News Today RAPP News Today SEPN News Today PGEN News Today STOK News Today CGEM News Today AUTL News Today VALN News Today XERS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTA Stock Alerts